ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials

December 31, 2010

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

December 14, 2007

First NCI Director To Resign Due To Presidential Election?

December 15, 2000

M.D. Anderson Stops Establishing Satellite Clinics, Views Role as Working With All Texas Oncologists

November 22, 1996

Momentum Continues For Private Development Of Free Standing Cancer Centers

July 19, 1985

NCI Pushing Ahead With Antismoking Campaign Involving Entire States, Physicians, Even Lawyers

March 27, 1987